<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE AND EXPERIMENTAL DESIGN: The role of RASSF1A has been elucidated recently in regulating <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and cell cycle progression by inhibiting cyclin D1 accumulation </plain></SENT>
<SENT sid="1" pm="."><plain>Aberrant RASSF1A promoter methylation has been found frequently in multiple adult <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> types </plain></SENT>
<SENT sid="2" pm="."><plain>Using methylation-specific PCR and reverse transcription-PCR, we investigated epigenetic deregulation of RASSF1A in <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e>, adjacent nontumor tissues, secondary <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e>, peripheral blood cells, and plasma samples from children with 18 different <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> types, in association with their clinicopathologic features </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Regardless of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> size, ubiquitous RASSF1A promoter methylation was found in 67% (16 of 24) of <z:e sem="disease" ids="C1368871" disease_type="Neoplastic Process" abbrv="">pediatric tumors</z:e>, including <z:hpo ids='HP_0003006'>neuroblastoma</z:hpo>, <z:hpo ids='HP_0002890'>thyroid carcinoma</z:hpo>, <z:hpo ids='HP_0001402'>hepatocellular carcinoma</z:hpo>, <z:hpo ids='HP_0100757'>pancreatoblastoma</z:hpo>, <z:hpo ids='HP_0006744'>adrenocortical carcinoma</z:hpo>, <z:e sem="disease" ids="C0027708" disease_type="Neoplastic Process" abbrv="">Wilms' tumor</z:e>, Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and T-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>A majority (75%) of <z:e sem="disease" ids="C0278704" disease_type="Neoplastic Process" abbrv="">pediatric cancer</z:e> patients with tumoral RASSF1A methylation was male </plain></SENT>
<SENT sid="5" pm="."><plain>Methylated RASSF1A alleles were also detected in 4 of 13 adjacent nontumor tissues, suggesting that this epigenetic change is potentially an early and critical event in childhood <z:hpo ids='HP_0002664'>neoplasia</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>RASSF1A promoter methylation found in 92% (11 of 12) of cell lines largely derived from <z:e sem="disease" ids="C0278704" disease_type="Neoplastic Process" abbrv="">pediatric cancer</z:e> patients was significantly associated with transcriptional silencing/repression </plain></SENT>
<SENT sid="7" pm="."><plain>After demethylation treatment with <z:chebi fb="0" ids="50131">5-aza-2'-deoxycytidine</z:chebi>, transcriptional reactivation was shown in KELLY, RD, and Namalwa cell lines as analyzed by reverse transcription-PCR </plain></SENT>
<SENT sid="8" pm="."><plain>For the first time, RASSF1A methylation was detected in 54% (7 of 13), 40% (4 of 10), and 9% (1 of 11) of buffy coat samples collected before, during, and after treatment, correspondingly, from pediatric patients with <z:hpo ids='HP_0003006'>neuroblastoma</z:hpo>, <z:hpo ids='HP_0002890'>thyroid carcinoma</z:hpo>, <z:hpo ids='HP_0001402'>hepatocellular carcinoma</z:hpo>, <z:hpo ids='HP_0002859'>rhabdomyosarcoma</z:hpo>, Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, T-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, or <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>Concordantly, RASSF1A methylation was found during treatment in plasma of the same patients, suggesting cell <z:hpo ids='HP_0011420'>death</z:hpo> and good response to chemotherapy </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: RASSF1A methylation in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> or buffy coat did not correlate strongly with age, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> size, recurrence/<z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e>, or overall survival in this cohort of <z:e sem="disease" ids="C0278704" disease_type="Neoplastic Process" abbrv="">pediatric cancer</z:e> patients </plain></SENT>
<SENT sid="11" pm="."><plain>Of importance, epigenetic inactivation of RASSF1A may potentially be crucial in <z:e sem="disease" ids="C1368871" disease_type="Neoplastic Process" abbrv="">pediatric tumor</z:e> initiation </plain></SENT>
</text></document>